Page 2 - Axsm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Axsm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Axsm Today - Breaking & Trending Today

Moody Aldrich Partners LLC Trims Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Moody Aldrich Partners LLC reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 9.2% in the fourth quarter, Holdings Channel reports. The firm owned 66,866 shares of the company’s stock after selling 6,767 shares during the period. Moody Aldrich Partners LLC’s holdings in Axsome Therapeutics were worth $5,322,000 at the […] ....

Nova Scotia , United States , Roger Jeffs , Markl Jacobson , Piper Sandler , Blackrock Inc , Vanguard Group Inc , Axsome Therapeutics Inc , Royal Bank , Moody Aldrich Partners , Holdings Channel , Cantor Fitzgerald , Securities Exchange Commission , Axsome Therapeutics , Free Report , Aldrich Partners , State Street Corp , Street Corp , Director Roger Jeffs , Exchange Commission , Get Free Report , Visit Holdingschannel , Axsome Therapeutics Daily , Nasdaq Axsm , Sec Filings , Hedge Fund Holdings ,

Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $190.00 price objective on the stock. Other analysts have also recently issued reports about the company. UBS Group initiated coverage on Axsome Therapeutics in a report on […] ....

United States , Roger Jeffs , Piper Sandler , Robertw Baird , Markl Jacobson , Axsome Therapeutics Inc , Axsome Therapeutics Company Profile , Goldman Sachs Group Inc , Eventide Asset Management , Vanguard Group Inc , Perceptive Advisors , Securities Exchange Commission , Axsome Therapeutics , Free Report , Moderate Buy , Therapeutics Stock Down , Get Free Report , Exchange Commission , Director Roger Jeffs , Asset Management , Sachs Group , Vanguard Group , Axsome Therapeutics Daily , Nasdaq Axsm , Reiterated Rating , Hc Wainwright ,

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells $1,904,892.88 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The sale was disclosed in a filing with the Securities & Exchange Commission, […] ....

Nova Scotia , United States , Markl Jacobson , Perceptive Advisors , Royal Bank , Vanguard Group Inc , Securities Exchange Commission , Axsome Therapeutics Inc , Blackrock Inc , Axsome Therapeutics Company Profile , Cantor Fitzgerald , Axsome Therapeutics , Get Free Report , Exchange Commission , Axsome Therapeutics Daily , Nasdaq Axsm , Insider Trading , Nsider Trades ,

HC Wainwright Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $190.00

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price raised by HC Wainwright from $180.00 to $190.00 in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Axsome Therapeutics’ Q2 2024 earnings at ($1.08) EPS, Q3 […] ....

United States , Robertw Baird , Roger Jeffs , Jpmorgan Chase Co , Axsome Therapeutics Company Profile , Metlife Investment Management , Sei Investments Co , Panagora Asset Management Inc , Raymond James Financial Services Advisors Inc , Axsome Therapeutics Inc , Axsome Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Roger Jeffs , James Financial Services Advisors , Life Investment Management , Asset Management , Sei Investments , Axsome Therapeutics Daily , Nasdaq Axsm , Boost Price Target , Hc Wainwright ,

Truist Financial Reiterates Buy Rating for Axsome Therapeutics (NASDAQ:AXSM)

Truist Financial restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Tuesday, Benzinga reports. The brokerage currently has a $150.00 price target on the stock. AXSM has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an overweight rating and set a $108.00 […] ....

United States , Roger Jeffs , Piper Sandler , Tower Research Capital , Cantor Fitzgerald , Harbour Investments Inc , Axsome Therapeutics Inc , Fifth Third Bancorp , Axsome Therapeutics Company Profile , Washington Trust Advisors Inc , Third Bancorp , Truist Financial , Axsome Therapeutics , Free Report , Moderate Buy , Get Free Report , Director Roger Jeffs , Trust Advisors , Financial Advisors , Research Capital , Axsome Therapeutics Daily , Nasdaq Axsm , Reiterated Rating , Truist Financial Co ,